[{"id":"273676e8-b129-4652-9a87-c66a21b29c53","acronym":"PanRAF","url":"https://clinicaltrials.gov/study/NCT02437227","created_at":"2021-01-19T14:08:36.690Z","updated_at":"2024-07-02T16:36:58.948Z","phase":"Phase 1","brief_title":"A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours","source_id_and_acronym":"NCT02437227 - PanRAF","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" RAS","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAL3833"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 04/15/2015","start_date":" 04/15/2015","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2019-06-12"}]